BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 9295863)

  • 1. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
    Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
    Gilbert CM; Filippich LJ; McGeary RP; Charles BG
    Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
    Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
    Ottosson S; Magnusson K; Hultborn R
    Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
    Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
    Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
    deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
    Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.
    Duska LR; Penson R; Supko JG; Finkelstein DM; Makastorsis T; Gallagher J; Borden K; Goodman A; Fuller AF; Nikrui N; Seiden MV
    Clin Cancer Res; 1999 Jun; 5(6):1299-305. PubMed ID: 10389912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
    Linden HM; Haskell CM; Green SJ; Osborne CK; Sledge GW; Shapiro CL; Ingle JN; Lew D; Hutchins LF; Livingston RB; Martino S
    J Clin Oncol; 2007 Feb; 25(6):656-61. PubMed ID: 17308269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
    Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration.
    Busse D; Würthwein G; Hinske C; Hempel G; Fromm MF; Eichelbaum M; Kroemer HK; Busch FW
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Sep; 366(3):218-25. PubMed ID: 12172704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of cremophor EL with bolus doxorubicin.
    Millward MJ; Webster LK; Rischin D; Stokes KH; Toner GC; Bishop JF; Olver IN; Linahan BM; Linsenmeyer ME; Woodcock DM
    Clin Cancer Res; 1998 Oct; 4(10):2321-9. PubMed ID: 9796961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.